Biocryst Pharmaceuticals (BCRX) Accumulated Expenses (2011 - 2026)

Biocryst Pharmaceuticals (BCRX) has 16 years of Accumulated Expenses data on file, last reported at $119.4 million in Q1 2026.

• Quarterly Accumulated Expenses rose 28.89% year-over-year to $119.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $119.4 million (up 28.89% YoY) and the FY2025 annual result came in at $126.4 million, up 11.58% from the prior year.
• Accumulated Expenses eased to $119.4 million in Q1 2026, from $126.4 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $126.4 million in Q4 2025 to a low of $63.6 million in Q1 2022.
• A 5-year average of $93.0 million and a median of $89.6 million in 2024 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 216.1% — and 2023, when it retreated 5.53%.
• Tracing BCRX's Accumulated Expenses over 5 years: stood at $87.6 million in 2022, then gained by 17.49% to $102.9 million in 2023, then increased by 10.12% to $113.3 million in 2024, then gained by 11.58% to $126.4 million in 2025, then fell by 5.55% to $119.4 million in 2026.
• The last three Accumulated Expenses figures came in at $119.4 million (Q1 2026), $126.4 million (Q4 2025), and $118.8 million (Q3 2025), per Business Quant data.